Evidence map›Paper›PMID 23061422›Full record

Trial reportAIDS research and human retroviruses2013

Partner characteristics predicting HIV-1 set point in sexually acquired HIV-1 among African seroconverters.

Jairam R Lingappa, Katherine K Thomas, James P Hughes, Jared M Baeten, Anna Wald, Carey Farquhar, Guy de Bruyn, Kenneth H Fife, Mary S Campbell, Saidi Kapiga and 3 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in AIDS research and human retroviruses, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 22 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. The natural history of HIV infection.Current opinion in HIV and AIDS · 2013
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Jairam R LingappaUniversity of Washington 325 Ninth Avenue, Box 359927 Seattle, WA 98104, USA. lingappa@uw.edu
Katherine K Thomas
James P Hughes
Jared M Baeten
Anna Wald
Carey Farquhar
Guy de Bruyn
Kenneth H Fife
Mary S Campbell
Saidi Kapiga
James I Mullins
Connie Celum
Partners in Prevention HSV/HIV Transmission Study Team
University of Washington · USFred Hutch Cancer Center · USIndiana University – Purdue University Indianapolis · USLondon School of Hygiene & Tropical Medicine · GBUniversity of the Witwatersrand · ZA

Funding

WOMEN'S HEALTH AGENDAU01AI038858 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI BENSON, CONSTANCE ANN · 1996 to 2008
$157.5M
University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI Kenneth Sherr · 1988 to 2026
$104.9M
THE PERINATAL COMPLICATIONS OF ASYMPTOMATIC GENITAL HERPES SIMPLEX VIRUSP01AI030731 · NIAID · UNIVERSITY OF WASHINGTON · PI ZHU, JIA · 1991 to 2017
$34.3M
Viral Determinants of HIV-1 Transmission in African HeterosexualsP01AI057005 · NIAID · UNIVERSITY OF WASHINGTON · PI COREY, LAWRENCE · 2003 to 2014
$20.5M
Medical Research Council G0901756NIAID NIH HHS AI 030731NIAID NIH HHS AI 27757NIAID NIH HHS AI 38858NIAID NIH HHS P01 AI030731NIAID NIH HHS P01 AI057005NIAID NIH HHS P30 AI027757
6 · The paper itself

Abstract

Plasma HIV-1 RNA set point is an important predictor of HIV-1 disease progression. We hypothesized that inoculum size and HIV-1 exposure prior to HIV-1 transmission may modulate set point. We evaluated predictors of set point among 141 African HIV-1 seroconverters and their HIV-1-infected study partners. We compared characteristics of seroconverters and their HIV-1-infected partners and HIV-1 set point. Data were from a clinical trial of genital HSV-2 suppression with acyclovir to reduce HIV-1 transmission in HIV-1 serodiscordant couples with HIV-1 transmission linkage assigned through virus sequencing. Our analysis includes data from all transmissions including those with transmission linkage to the HIV-1-infected "source partner" and those that were not linked to their HIV-1-infected study partner. In multivariable analysis, higher plasma HIV-1 in source partners was associated with higher seroconverter set point ( + 0.44 log10 copies/ml per log(10) source partner plasma HIV-1, p < 0.001). In addition, bacterial vaginosis (BV) among female source partners near the time of infection was associated with higher set point in their male seroconverters ( + 0.49 log(10), p = 0.04). Source partner characteristics associated with lower set point included male circumcision ( - 0.63 log(10), p = 0.03) and assignment to acyclovir ( - 0.44 log10, p = 0.02). The proportion of variation in set point explained by plasma HIV-1 RNA of the source partner, after controlling for other factors, was 0.06. Source partner plasma HIV-1 level is the most significant predictor of seroconverter set point, possibly reflecting characteristics of the transmitted virus. Acyclovir use, BV among women source partners, and circumcision among male source partners may alter the set point by affecting transmitted virus inoculum in the source partners' genital compartment.

Indexed as

HIV-1AcyclovirAdultAntiviral AgentsCircumcision, MaleFemaleHerpes GenitalisHIV InfectionsHIV SeropositivityHumansMaleRisk FactorsRNA, ViralSex FactorsSexual PartnersTime FactorsAcyclovirAntiviral AgentsRNA, Viral

Identifiers

PMID23061422
PMCPMC3537302
OpenAlexW1982416473

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.